Article Text

Download PDFPDF
Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q Is clozapine more effective than other second-generation antipsychotics for people with resistant schizophrenia?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Single blind (assessors blinded).

Embedded ImageFollow-up period:

Twelve months.

Embedded ImageSetting:

Five centres, UK; time period not stated.

Embedded ImagePatients:

136 adults (18–65 years old) with DSM-IV schizophrenia, schizoaffective or delusional disorder and poor clinical response to at least two other treatments. Exclusions: neuroleptic malignant disorder, substance misuse or medical disorder responsible for psychotic symptoms.

Embedded ImageIntervention:

Clozapine (end dose range 100–600 mg/day; mean end dose 333 mg/day) or other second-generation antipsychotic (amisulpride 600–800 mg/day (mean 683 mg/day), olanzapine 10–30 mg/day …

View Full Text


  • For correspondence: Shôn W Lewis, University of Manchester, Manchester, UK; shon.lewis{at}

  • Source of funding: NHS Technology Assessment Program, UK.